Literature DB >> 32332076

Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation.

Yueting Li1, Jianwei Huo2, Yihan Cao3, Meiyan Yu2, Yanan Zhang2, Zhaohui Li4, Chen Li5, Wen Zhang6.   

Abstract

Entities:  

Keywords:  DMARDs (synthetic); autoimmune diseases; magnetic resonance imaging; spondyloarthritis

Mesh：

Substances：

Year:  2020        PMID： 32332076     DOI： 10.1136/annrheumdis-2020-217250

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   27.973


× No keyword cloud information.
  6 in total

1.  SAPHO Syndrome Complicated by Ankylosing Spondylitis Successfully Treated With Tofacitinib: A Case Report.

Authors:  Fangfang Yuan; Jing Luo; Qiong Yang
Journal:  Front Immunol       Date:  2022-05-25       Impact factor: 8.786

2.  [SAPHO syndrome : An overview and nosological differentiation of 35 disease cases].

Authors:  Philipp Klemm; Uwe Lange
Journal:  Z Rheumatol       Date:  2021-03-16       Impact factor: 1.372

3.  Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome of femoral neoplasm-like onset: a case-based review.

Authors:  Cheng Qiu; Lin Cheng; Haodong Hou; Tianyi Liu; Bohan Xu; Xing Xiao; Zhankui Wang; Qing Wang
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

Review 4.  New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.

Authors:  Wei Cheng; Fen Li; Jing Tian; Xi Xie; Jin-Wei Chen; Xiao-Fei Peng; Qi Tang; Yan Ge
Journal:  J Inflamm Res       Date:  2022-04-13

5.  Coexistence of Sjögren syndrome in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: A retrospective observational study.

Authors:  Lun Wang; Yanying Yu; Shuo Zhang; Wen Zhang; Chen Li
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

Review 6.  New insights on multigenic autoinflammatory diseases.

Authors:  Petros Efthimiou; Olga Petryna; Priscila Nakasato; Apostolos Kontzias
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-03       Impact factor: 3.625
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.